ARTV

Artiva Biotherapeutics, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

bullishMay 8

FDA alignment on a single registrational Phase 3 trial design for refractory RA.

guidance raise

80%

bearishMay 8

Cash runway extending only to Q2 2027 against high-cost Phase 3 requirements.

dilution risk

70%

bearishMay 8

Significant accumulated deficit of $354.1 million and ongoing quarterly losses.

margin compression

50%

Filing History

10-QMay 8, 2026

The 10-Q reveals a company at a critical inflection point, where scientific validation is clashing with financial reality. The alignment with the FDA on a registrational trial design is a major catalyst that validates the AlloNK platform's potential in autoimmune diseases. However, the gap between current liquidity and the capital requirements for a global Phase 3 trial remains the primary headwind for investors. The overall impact of the filing is a shift in risk profile from 'scientific' to 'execution and financial.' While the clinical data is compelling, the market must now weigh the probability of successful Phase 3 execution against the likelihood of significant share dilution. The coming months will be defined by Artiva's ability to activate trial sites and secure the substantial capital necessary to bridge the gap to a 2028 efficacy readout.